Physician profile
Jeannie M Merrick
NPI 1346272895
$1,020.25
in general payments reported to CMS, 2019-2025
20 companies · $287 in 2025
The $287 reported for 2025 was more than what 77% of Women'S Health Care, Ambulatory providers received nationally (typical 2025 total: $102).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $165 · 2023: $159 · 2024: $249 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $288.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $127.95 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.35 | 2024-2025 | Jardiance |
| Abbvie INC. | $78.12 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $67.27 | 2022-2023 | Livalo |
| Amgen INC. | $61.97 | 2021-2023 | Repatha, Otezla |
| Mannkind Corporation | $43.24 | 2021 | |
| Nalu Medical, INC. | $28.97 | 2023 | Nalu Neurostimulation System |
| Sanofi-Aventis U.S. LLC | $27.34 | 2022 | |
| Novo Nordisk INC | $20.18 | 2025 | |
| Lilly USA, LLC | $19.33 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $18.97 | 2023 | Flumist Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $17.94 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $17.69 | 2024 | Spravato |
| Abbott Laboratories | $17.12 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.11 | 2024 | Trelegy Ellipta |
| Gilead Sciences, INC. | $15.96 | 2025 | |
| Aimmune Therapeutics, INC. | $14.67 | 2025 | Zenpep |
| Amarin Pharma, INC. | $14.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeannie Merrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.